AstraZeneca expands deal with ImaginAb; Ovid posts promising data on Takeda-partnered seizure drug
→ On a day when AstraZeneca issued a flurry of updates on three of its blockbuster therapies, the British drugmaker also expanded its deal with ImaginAb, an immuno-oncology imaging company. The partnership gives AstraZeneca access to ImaginAb’s CD8 ImmunoPET technology, which is a diagnostic approach used to non-invasively measure the effect of immunotherapies. The financial details of the deal were not disclosed.
→ Ovid Therapeutics reported data from the initial 11 patients testing its Takeda-partnered experimental drug, soticlestat, in patients with rare forms of epilepsy. The results suggest the drug is safe and well-tolerated and appears to reduce seizure frequency in a majority of the individual patients. The full dataset is expected to be posted in the first quarter of 2021.
→ Inovio’s experimental therapy, VGX-3100, which is being evaluated in a late-stage study, was shown to have a beneficial impact in patients in a small open-label mid-stage trial in women with vulvar dysplasia, a precancerous condition caused by high-risk human papillomavirus (HPV).